Liver，Kidney and Immunologic Function and Drug Resistance in Patients with Nontuberculous Mycobacteria Infection

Xinrui WAN; Xiaoyan WANG; Lin WANG; Zhiqiang MA; Caixin LI; Shitao XU; Xingrui TANG; Hongyan Mao

doi:10.12259/j.issn.2095-610X.S20231117

Volume 44 Issue 11

Nov. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(11): 113-119

Xinrui WAN, Xiaoyan WANG, Lin WANG, Zhiqiang MA, Caixin LI, Shitao XU, Xingrui TANG, Hongyan Mao. Liver，Kidney and Immunologic Function and Drug Resistance in Patients with Nontuberculous Mycobacteria Infection[J]. Journal of Kunming Medical University, 2023, 44(11): 113-119. doi: 10.12259/j.issn.2095-610X.S20231117

Citation:

Xinrui WAN, Xiaoyan WANG, Lin WANG, Zhiqiang MA, Caixin LI, Shitao XU, Xingrui TANG, Hongyan Mao. Liver，Kidney and Immunologic Function and Drug Resistance in Patients with Nontuberculous Mycobacteria Infection[J]. Journal of Kunming Medical University, 2023, 44(11): 113-119. doi: 10.12259/j.issn.2095-610X.S20231117

Citation:

Xinrui WAN, Xiaoyan WANG, Lin WANG, Zhiqiang MA, Caixin LI, Shitao XU, Xingrui TANG, Hongyan Mao. Liver，Kidney and Immunologic Function and Drug Resistance in Patients with Nontuberculous Mycobacteria Infection[J]. Journal of Kunming Medical University, 2023, 44(11): 113-119. doi: 10.12259/j.issn.2095-610X.S20231117

PDF( 702 KB)

Liver，Kidney and Immunologic Function and Drug Resistance in Patients with Nontuberculous Mycobacteria Infection

doi: 10.12259/j.issn.2095-610X.S20231117

Dept. of Laboratory，The 3rd People’s Hospital of Kunming/Yunnan Province Communicable Disease Clinical Medical Center，Kunming Yunnan 650301，China

Received Date: 2023-08-31
Publish Date: 2023-11-25

Abstract

Abstract

Objective To analyze the differences in liver and kidney function, immune function, and drug resistance between nontuberculous mycobacteria-infected people and healthy people. Methods We collected 122 cases of Nontuberculous Mycobacterium infected people and 130 cases of Mycobacterium tuberculosis-infected people in The Third People’ s Hospital of Kunming from May 2021 to March 2022, which were divided into non-Mycobacterium tuberculosis group and tuberculosis group respectively. And 150 cases of healthy people in the same period were selected as a healthy control group. We analyzed the difference in sex, age, liver and kidney function, peripheral blood T lymphocyte subsets and drug sensitivity tests between three groups. Results There was no significant difference between the non-tuberculosis group, tuberculosis group, and healthy group in different ages and sexes（P > 0.05）. The TBIL, ALT, AST, GGT, CR and UA of the non-tuberculosis group were significantly higher than those in the tuberculosis group and healthy group（ P < 0.05）. TBIL, ALT, AST and GGT in the non-tuberculosis group were significantly higher than those in the tuberculosis group（ P < 0.05）. The CD3 ⁺T, CD4⁺T and CD8⁺T lymphocyte count in the non-tuberculosis group and tuberculosis group were significantly lower than those in the healthy group（P < 0.05）. The CD8 ⁺T lymphocyte count in the non-tuberculosis group was significantly higher than that in the tuberculosis group（P < 0.05）. The top three drug-resistance medicines in the non-tuberculosis group were imine/doxycycline, doxycycline and minocycline, and the drug resistance rates were 99.18%, 78.69% and 72.95% respectively. The top three drug resistance medicine in the tuberculosis group were isoniazid, rifampicin, and rifapentine, and the drug resistance rates were 22.32%, 17.69% and 16.15% respectively. Conclusion Compared with Mycobacterium tuberculosis, a non-Mycobacterium tuberculosis-infected person has more serious liver function damage, and the immune function is prone to disorder and damage. Non-tuberculous mycobacteria are more resistant to antibiotics, and the drug resistance is stronger. We should strengthen the identification of non-tuberculous mycobacteria and mycobacterium tuberculosis infection in a clinic and use the drug regimen reasonably.
- Nontuberculous mycobacteria,
- Mycobacterium tuberculosis,
- Lymphocyte subsets,
- Drug resistence

FullText(HTML)

References(18)

References

[1]	Gopalaswmy R,Shanmugam S,Mondal R,et al. Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology,diagnosis and treatment[J]. J Biomed Sci,2020,27(1):74. doi: 10.1186/s12929-020-00667-6
[2]	Mbeha B,Mine M,Motswaledi M S,et al. Nontuberculous mycobacteria,botswana,2011–2014[J]. Emerging Infectious Diseases,2019,25(7):1401-1403. doi: 10.3201/eid2507.181440
[3]	Han S A, Ko Y, Shin S J, et al. Characteristics of Circulating CD4+ T Cell Subsets in Patients with Mycobacterium avium Complex Pulmonary Disease [J]. Journal of Clinical Medicine, 2020;9 （5）: 1331页码 Han S A,Ko Y,Shin S J,et al. Characteristics of circulating CD4+ T cell subsets in patients with mycobacterium avium complex pulmonary disease[J]. Journal of Clinical Medicine,2020,9(5):1331.
[4]	中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 非结核分枝杆菌病诊断与治疗专家共识. 中华结核和呼吸杂志, 2012, 35（8）: 572-580.
[5]	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 肺结核基层诊疗指南（2018年）. 中华全科医师杂志, 2019, 18（8）: 709-717.
[6]	Yang C,Luo X,Fan L,et al. Performance of interferon-gamma release assays in the diagnosis of nontuberculous mycobacterial diseases-A retrospective survey from 2011 to 2019[J]. Front Cell Infect Microbiol,2020,10:571230.
[7]	Tan Y,Su B,Shu W,et al. Epidemiology of pulmonary disease due to nontuberculous mycobacteria in Southern China,2013-2016[J]. BMC Pulm Med,2018,18(1):168. doi: 10.1186/s12890-018-0728-z
[8]	Hussain Z,Zhu J,Ma X. Metabolism and hepatotoxicity of pyrazinamide,an antituberculosis drug[J]. Drug Metabolism and Disposition,2021,49(8):679-682. doi: 10.1124/dmd.121.000389
[9]	Xu N,Yang J X,Yang J. Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan,China[J]. European Journal of Hospital Pharmacy,2022,29(4):217-221. doi: 10.1136/ejhpharm-2020-002433
[10]	Liu L,Li X,Huang C,et al. Bile acids,lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs[J]. Expert Opinion on Drug Metabolism & Toxicology,2020,16(6):527-537.
[11]	欧阳国泉,陈盛松,肖祖克. 非结核分枝杆菌肺病和肺结核患者的临床特征分析中国呼吸与危重监护杂志[J]. 中国呼吸与危重监护杂志,2021,20(11):774-779.
[12]	Cruz‐Aguilar M,Castillo‐Rodal A I,Arredondo‐HernÁndez R,et al. Non‐tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade‐off and NTM ways into virulence[J]. Scandinavian Journal of Immunology,2021,94(2):e13035. doi: 10.1111/sji.13035
[13]	Abebe F. Is interferon-gamma the right marker for bacille Calmette–Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology[J]. Clinical and Experimental Immunology,2012,169(3):213-219. doi: 10.1111/j.1365-2249.2012.04614.x
[14]	Daley C L,Iaccarino J M,Lange C,et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline[J]. Clin Infect Dis,2020,71(4):e1-e36. doi: 10.1093/cid/ciaa241
[15]	Parish I A,Heath W R. Too dangerous to ignore: Self-tolerance and the control of ignorant autoreactive T cells[J]. Immunol Cell Biol,2008,86(2):146-152. doi: 10.1038/sj.icb.7100161
[16]	杨燕,曾谊. 非结核分枝杆菌肺病170例回顾性分析[J]. 南京医科大学学报(自然科学版),2021,41(7):1058-1062.
[17]	Mvubu N E,Pillay B,Pillay M. Infection of pulmonary epithelial cells by clinical strains of M. tuberculosis induces alternate splicing events[J]. Gene,2020,750:144755. doi: 10.1016/j.gene.2020.144755
[18]	宋育明,杨映晖,董春萍. 分枝杆菌感染的特征和耐药性分析[J]. 中国药物滥用防治杂志,2022,28(2):240-244,259.

Relative Articles(20)

Relative Articles

[1]	Yanzhu YIN, Zushun YANG, Yanqiushuo ZOU, Xiang REN, Yidan GUO, Lu FAN. Investigation of Molecular Typing and Drug Resistance of Shigella in Yunnan Province from 2016 to 2022. Journal of Kunming Medical University, 2024, 45(7): 79-86. doi: 10.12259/j.issn.2095-610X.S20240712
[2]	Jibo QU, Ling ZHU, Binghui HOU, Song BAI, Anmu XIE. Early predictive value of lymphocyte subsets for cognitive dysfunction in cerebral ischemia-reperfusion injury. Journal of Kunming Medical University, 2024, 46(): 1-5.
[3]	Xinye YANG, Nian ZHANG, Sha MA, Linpei HUANG, Xueyi LI, Xiaoping HUANG, Mi ZHANG, Cuixian YANG, Xicheng WANG. Analysis of Laboratory Index Characteristics in Newly Treated Smear-Negative Pulmonary Tuberculosis Patients. Journal of Kunming Medical University, 2024, 45(9): 56-61. doi: 10.12259/j.issn.2095-610X.S20240909
[4]	Xiaoyan WANG, Ya LI, Chenglu HE, Lin WANG, Zhiqiang MA, Xinrui WAN. Study on Immune Function and Drug Resistance of Tuberculosis Patients Co-infected with HBV，HCV and HIV in Yunnan. Journal of Kunming Medical University, 2023, 44(12): 51-58. doi: 10.12259/j.issn.2095-610X.S20231209
[5]	Lianyong CHEN, Xing YANG, Haohao RU, Tao CHEN, Shuangqun YAN, Lin XU. Analysis of Molecular Characteristics of Mycobacterium Tuberculosis and Factors Associated with Transmission in Yunnan Province. Journal of Kunming Medical University, 2023, 44(8): 1-7. doi: 10.12259/j.issn.2095-610X.S20230821
[6]	Liju ZHANG, Xiaoming JIANG, Changxian CHEN, Xi WU, Zhenyong ZHANG, Weijun LIU. Long Non-coding RNA-p21 Regulates the MicroRNA-9 / Sirtuin-1 Signaling Pathway to Reverse Oxaliplatin Resistance in Colorectal Cancer Cells. Journal of Kunming Medical University, 2022, 43(5): 27-32. doi: 10.12259/j.issn.2095-610X.S20220519
[7]	Bo TIAN, Yinzhong SHEN, Jinsong BAI, Jun LIU, Haiyun CHEN, Jianjun SUN. Clinical Characteristics of Talaromyces Marneffei Disease and Disseminated Nontuberculosis Mycobacterium Disease in AIDS Patients. Journal of Kunming Medical University, 2022, 43(7): 140-144. doi: 10.12259/j.issn.2095-610X.S20220718
[8]	Lianyong CHEN, Haohao RU, Xing YANG, Shuangqun YAN, Tao CHEN, Qinxuan NI, Lin XU. Characteristics of katG and inhA Gene Mutations in INH-Resistant Mycobacterium Tuberculosis in Yunnan Province. Journal of Kunming Medical University, 2022, 43(8): 28-33. doi: 10.12259/j.issn.2095-610X.S20220803
[9]	Fu-Jun ZHANG, Rong GONG. Significance of Dynamic Monitoring of T Lymphocyte Subsets and NK Cells in Patients with Esophageal Cancer before and after the Surgery and Chemotherapy. Journal of Kunming Medical University, 2021, 42(9): 46-50. doi: 10.12259/j.issn.2095-610X.S20210935
[10]	Chen Lian Yong , Ru Hao Hao , Yang Xing , Yan Shuang Qun , Chen Jin Ou , Yang Rui , Chen Tao , Xu Lin . . Journal of Kunming Medical University, 2020, 41(03): 45-49.
[11]	Xiao-qin LI, Min ZHOU, Lin WANG, Hai-yan ZENG, Peng-ju LUO, Li-jia LIN. Efficacy of PCR-reverse Dot Hybridization in Drug Resistance Gene Detection and Drug Sensitivity of BD960 Tuberculosis in Drug Resistance Tuberculosis Detection. Journal of Kunming Medical University, 2020, 41(12): 138-141. doi: 10.12259/j.issn.2095-610X.S20201238
[12]	Li Xiao Qin , Zhou Min , Wang Lin , Zeng Hai Yan , Luo Peng Ju , Li Ying , Ran Li Quan . Comparative Analysis of Rifampicin-resistant Mutant Gene Detection of Mycobacterium Tuberculosis and Drug Sensitivity BD960. Journal of Kunming Medical University, 2019, 40(03): 112-115.
[13]	Ren Xiao Yan , Mao Jian . Surveillance of Antimicrobial Resistance of Haemophilus influenzae in First Affiliated Hospital of Kunming Medical University during 2012 and 2015. Journal of Kunming Medical University, 2017, 38(10): 45-49.
[14]	Mao Jian , Ren Yu Ji , Dan Bin , Shao Tian Bo . The Distribution and Drug-resistance of Gram-negative Bacilli among Blood Stream Infection in Yunnan Province of China during 2012～2014. Journal of Kunming Medical University, 2016, 37(12): 24-28.
[15]	Liu Shu Min . Distribution and Drug Resistance of Carbapenem-resistant Citrobacter Freundii from 2012 to 2014. Journal of Kunming Medical University,
[16]	Zhao Xiao Li . . Journal of Kunming Medical University,
[17]	Jing Xiao Jie . . Journal of Kunming Medical University,
[18]	Chen Lian Yong . . Journal of Kunming Medical University,
[19]	Mao Jian . . Journal of Kunming Medical University,
[20]	Li Xiao Fei . . Journal of Kunming Medical University,